HRP20161739T1 - VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa - Google Patents
VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa Download PDFInfo
- Publication number
- HRP20161739T1 HRP20161739T1 HRP20161739TT HRP20161739T HRP20161739T1 HR P20161739 T1 HRP20161739 T1 HR P20161739T1 HR P20161739T T HRP20161739T T HR P20161739TT HR P20161739 T HRP20161739 T HR P20161739T HR P20161739 T1 HRP20161739 T1 HR P20161739T1
- Authority
- HR
- Croatia
- Prior art keywords
- cnp37
- seq
- dysplasia
- taf12
- cnp variant
- Prior art date
Links
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 title claims 15
- 101800000060 C-type natriuretic peptide Proteins 0.000 title claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 101000788172 Homo sapiens Transcription initiation factor TFIID subunit 12 Proteins 0.000 claims 10
- 102100025171 Transcription initiation factor TFIID subunit 12 Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 230000004927 fusion Effects 0.000 claims 7
- 238000003776 cleavage reaction Methods 0.000 claims 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 3
- 206010008723 Chondrodystrophy Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 235000019253 formic acid Nutrition 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 2
- 208000008919 achondroplasia Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000017568 chondrodysplasia Diseases 0.000 claims 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 201000010072 hypochondroplasia Diseases 0.000 claims 2
- 231100000518 lethal Toxicity 0.000 claims 2
- 230000001665 lethal effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 claims 1
- 101100424399 Caenorhabditis elegans taf-12 gene Proteins 0.000 claims 1
- 208000009447 Cardiac Edema Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 108010013369 Enteropeptidase Proteins 0.000 claims 1
- 102100029727 Enteropeptidase Human genes 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 208000016264 Femoral agenesis/hypoplasia Diseases 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049933 Hypophosphatasia Diseases 0.000 claims 1
- 102000004195 Isomerases Human genes 0.000 claims 1
- 108090000769 Isomerases Proteins 0.000 claims 1
- 208000001182 Kniest dysplasia Diseases 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 208000008063 Langer mesomelic dysplasia Diseases 0.000 claims 1
- 206010024503 Limb reduction defect Diseases 0.000 claims 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims 1
- 208000011262 Micromelia Diseases 0.000 claims 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000032158 Nievergelt type mesomelic dwarfism Diseases 0.000 claims 1
- -1 ProTEV Proteins 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000001718 Roberts syndrome Diseases 0.000 claims 1
- 208000005568 Robinow syndrome Diseases 0.000 claims 1
- 208000020221 Short stature Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 102100036407 Thioredoxin Human genes 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 208000005065 achondrogenesis Diseases 0.000 claims 1
- 201000007047 acrodysostosis Diseases 0.000 claims 1
- 208000001884 acromesomelic dysplasia Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 201000007845 atelosteogenesis Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000008468 bone growth Effects 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000007394 diastrophic dysplasia Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000003350 fibrochondrogenesis Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000010828 metaphyseal dysplasia Diseases 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 235000006109 methionine Nutrition 0.000 claims 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 1
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 claims 1
- 210000002464 muscle smooth vascular Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 208000027612 peripheral dysostosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000003580 polydactyly Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000010809 spondyloepimetaphyseal dysplasia Diseases 0.000 claims 1
- 206010062920 spondyloepiphyseal dysplasia Diseases 0.000 claims 1
- 201000002962 spondyloepiphyseal dysplasia with congenital joint dislocations Diseases 0.000 claims 1
- 201000003896 thanatophoric dysplasia Diseases 0.000 claims 1
- 229940035024 thioglycerol Drugs 0.000 claims 1
- 108060008226 thioredoxin Proteins 0.000 claims 1
- 229940094937 thioredoxin Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Varijanta natriuretičnog peptida C-tipa (CNP) naznačen time da je odabrana iz skupine koju čine:
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Pro-Gly-CNP37)(SEQIDNO:145);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Pro-CNP37) (SEQIDNO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-CNP37) (SEQIDNO: 192);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-Gly-CNP37) (SEQ ID NO: 191).
2. Farmaceutski pripravak naznačen time da sadrži CNP varijantu prema zahtjevu 1, te farmaceutski prihvatljivu pomoćnu tvar, nosač ili dodatak otapalu.
3. Farmaceutski pripravak prema zahtjevu 2, naznačen time daje liofilizirani pripravak pripravljen iz formulacije koja sadrži limunsku kiselinu/citratni pufer ili octenu kiselinu /acetatni pufer koja ima pH od oko 4 do oko 6, pri čemu formulacija proizvoljno dodatno sadrži sredstvo za podešavanje izotoničnosti i/ili sredstvo za povećavanje volumena, i/ili nadalje sadrži antioksidans koji je odabran iz skupine koju čine metionin, askorbinska kiselina, oblici soli askorbinske kiseline, tioglicerol, i njihove kombinacije.
4. CNP varijanta prema zahtjevu 1 ili farmaceutski pripravak prema bilo kojem od zahtjeva 2 ili 3, naznačen time daje za uporabu u postupku za liječenje poremećaja povezanog s kostima ili skeletne displazije koji su odabrani iz skupine koja se sastoji od osteoartritisa, hipofosfatemijskog rahitisa, ahondroplazije, hipohondroplazije, niskog rasta, patuljastog rasta, osteohondrodisplazija, tanatoforne displazije. osteogenesis imperfecta, ahondrogeneze, homozigotne ahondroplazije, hondrodisplazije punktata, kamptomelijske displazije, kongenitalne smrtonosne hipofosfatazije, perinatalnog smrtonosnog tipa osteogenesis imperfecta, sindroma polidaktilije s kratkim rebrima, hipohondroplazije, rizomelijskog tipa hondrodisplazije punktata, Jansenovog tipa metafizalne displazije, spondiloepifizealne displazije kongenita, atelosteogeneze, dijastrofične displazije, kongenitalnog kratkog femura, Langerovog tipa mezomelične displazije, Nievergeltovog tipa mezomelične displazije, Robinowog sindroma, Reinhardtovog sindroma, akrodisostoze, periferne disostoze, Kniestove displazije, fibrohondrogeneze, Robertsovog sindroma, akromezomelične displazije, mikromelije, Morquio sindroma, Kniestovog sindroma, metatrofične displazije, te spondiloepimetafizealne displazije.
5. CNP varijanta prema zahtjevu 1 ili farmaceutski pripravak prema zahtjevu 2 ili 3, naznačen time da je za uporabu u postupku za liječenje vaskularnog poremećaja glatkih mišića koji je odabran iz skupine koju čine hipertenzija, restenoza, arterioskleroza, akutno dekompenzacijsko zatajenje srca, kongestivno zatajenje srca, srčani edem, bubrežni edem, jetreni edem, akutna insuficijencija bubrega, te kronična insuficijencija bubrega.
6. Postupak za rekombinantnu proizvodnju CNP varijante prema zahtjevu 1, naznačen time da sadrži
(i) kultiviranje bakterijske stanice domaćina koja sadrži prvi polinukleotid koji kodira CNP varijantu polipeptida prema zahtjevu 1 vezan na drugi polinukleotid koji kodira cijepajući peptid ili bjelančevina pod uvjetima koji rezultiraju ekspresijom fuzijskog polipeptida koji je kodiran s navedenim prvim i drugim polinukleotidima, pri čemu fuzijski polipeptid sadrži navedenu CNP varijantu izravno vezanu na navedeni cijepajući peptid ili bjelančevina ili neizravno vezanu na njih preko poveznice i pri čemu je cijepajući peptid ili bjelančevina odabran iz skupine koju čine histidinske oznake, ljudski transkripcijski faktor TAF12, TAF12 histonska višekratna domena, TAF12(C/A), TAF12(D/E), TAF12(4D/4E), TAF12(6D/6E), TAF 12(1 OD/1 OE), TAF12(C/A & D/E), TAF12(C/A & 4D/4E), TAF12(C/A & 6D/6E), TAF12(C/A & 10D/10E), ketosteroidna izomeraza, bjelančevina koja veže maltozu, β-galaktozidaza, glutation-S-transferaza, tioredoksin, domena koja veže hitin, BMP-2, i BMP-2(C/A), i
(ii) cijepanje navedenog cijepajućeg peptida ili bjelančevina iz navedenog fuzijskog polipeptida radi oslobađanja navedene CNP varijante.
7. Postupak prema zahtjevu 6, naznačen time da je fuzijski polipeptid eksprimiran kao topivi bjelančevina ili kao inkluzijsko tijelo, te dodatno sadrži izoliranje eksprimiranog fuzijskog polipeptida iz stanice domaćina ili medija za kultiviranje.
8. Postupak prema zahtjevu 6 ili 7, naznačen time da nadalje sadrži dovođenje u kontakt izoliranog fuzijskog polipeptida sa sredstvom za cijepanje koje se bira iz skupine koju čine mravlja kiselina, cijanogen bromid (CNBr), hidroksilamin, samo cijepajući bjelančevina, Faktor Xa, enterokinaza, ProTEV, i SUMO proteaza.
9. Postupak prema zahtjevu 8, naznačen time da sredstvo za cijepanje je mravlja kiselina, te pri čemu se dovođenje u kontakt izoliranog fuzijskog polipeptida sa sredstvom za cijepanje provodi u prisutnosti od oko 1% do oko 10% mravlje kiseline kod temperature od oko 50 °C do oko 70 °C u vremenskom periodu od oko 5 sati do oko 36 sati.
10. Postupak prema bilo kojem od zahtjeva 6 do 9, naznačen time da proizvodi CNP varijantu koja je odabrana iz skupine koju čine:
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Pro-CNP37) (SEQIDNO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-CNP37) (SEQIDNO: 192);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (Pro-Gly-CNP37)(SEQIDNO: 145); i
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-Gly-CNP37)(SEQ1DNO: 191).
11. CNP varijanta proizvedena prema postupka prema bilo kojem od zahtjeva 6 do 9, naznačena time da je CNP varijanta odabrana iz skupine koju čine:
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Pro-CNP37) (SEQIDNO: 186);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-CNP37) (SEQIDNO: 192);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRlGSMSGLGC(Pro-Gly-CNP37)(SEQIDNO: 145); i
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-Gly-CNP37)(SEQIDNO: 191).
12. CNP varijanta za uporabu u postupku za povećavanje dugog rasta kostiju, naznačena time da je CNP varijanta odabrana od: (SEQIDNO: 192) MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-CNP37); (SEQIDNO: 186) PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Pro-CNP37); (SEQIDNO: 145) PGQEHPNARKYKGANKKGLSKGCFGLKLDRlGSMSGLGC(Pro-Gly-CNP37)); i (SEQIDNO: 191) MGQEHP NARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC(Met-Gly-CNP37)).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18011209P | 2009-05-20 | 2009-05-20 | |
| US25456309P | 2009-10-23 | 2009-10-23 | |
| EP10778389.6A EP2432489B1 (en) | 2009-05-20 | 2010-05-20 | Variants of c-type natriuretic peptide |
| PCT/US2010/035586 WO2010135541A2 (en) | 2009-05-20 | 2010-05-20 | Variants of c-type natriuretic peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161739T1 true HRP20161739T1 (hr) | 2017-03-10 |
Family
ID=43124672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220057TT HRP20220057T1 (hr) | 2009-05-20 | 2010-05-20 | Varijante natriuretičnog peptida c-tipa |
| HRP20161739TT HRP20161739T1 (hr) | 2009-05-20 | 2016-12-19 | VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220057TT HRP20220057T1 (hr) | 2009-05-20 | 2010-05-20 | Varijante natriuretičnog peptida c-tipa |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US8198242B2 (hr) |
| EP (3) | EP4029512A1 (hr) |
| JP (1) | JP5718909B2 (hr) |
| KR (5) | KR20230142644A (hr) |
| CN (1) | CN102481330B (hr) |
| AR (1) | AR078044A1 (hr) |
| AU (1) | AU2010249802B2 (hr) |
| BR (2) | BRPI1012783B1 (hr) |
| CA (1) | CA2758581C (hr) |
| CL (1) | CL2011002430A1 (hr) |
| DK (2) | DK3175863T3 (hr) |
| ES (2) | ES2904360T3 (hr) |
| FI (1) | FIC20220003I1 (hr) |
| FR (1) | FR22C1004I2 (hr) |
| HK (1) | HK1168279A1 (hr) |
| HR (2) | HRP20220057T1 (hr) |
| HU (3) | HUE057174T2 (hr) |
| IL (1) | IL215287A (hr) |
| MX (1) | MX2011012277A (hr) |
| NO (1) | NO2022003I1 (hr) |
| PE (1) | PE20120792A1 (hr) |
| PL (2) | PL3175863T3 (hr) |
| PT (2) | PT2432489T (hr) |
| RU (1) | RU2573911C2 (hr) |
| TW (1) | TWI471137B (hr) |
| WO (1) | WO2010135541A2 (hr) |
| ZA (1) | ZA201107087B (hr) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3404102T3 (pl) | 2004-04-21 | 2021-12-13 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
| ES2904360T3 (es) * | 2009-05-20 | 2022-04-04 | Biomarin Pharm Inc | Variantes de péptido natriurético de tipo C |
| KR101226165B1 (ko) * | 2009-07-23 | 2013-01-24 | 가부시키가이샤 이기스 | 피부 외용제 조성물 |
| MX2012002175A (es) * | 2009-08-27 | 2012-06-27 | Igisu Co Ltd | Preparacion terapeutica para la rinitis. |
| KR20130118203A (ko) | 2010-04-30 | 2013-10-29 | 알렉시온 파마 인터내셔널 에스에이알엘 | 매트릭스 무기물화 장애의 처리방법, 조성물 및 키트 |
| AU2011350066A1 (en) | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| US20120277155A1 (en) | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| WO2013016148A2 (en) * | 2011-07-27 | 2013-01-31 | Medtronic, Inc. | Natriuretic peptide compositions and methods of preparation |
| EP2750697A4 (en) * | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| CA2852874A1 (en) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| EP3088416B1 (en) * | 2011-12-23 | 2019-02-27 | Mayo Foundation for Medical Education and Research | Assessing renal structural alterations and outcomes |
| EP2853273A4 (en) * | 2012-04-25 | 2016-01-13 | Daiichi Sankyo Co Ltd | PROMOTER FOR BONE REPAIR |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| CN104870020A (zh) * | 2012-10-19 | 2015-08-26 | 康奈尔大学 | 用于关节软骨的仿生型界面润滑剂 |
| CN104619326A (zh) * | 2013-03-10 | 2015-05-13 | 国立大学法人名古屋大学 | 骨系统疾病治疗药及其用途 |
| CN103159847B (zh) * | 2013-04-12 | 2014-05-28 | 叶亮 | 一种利钠肽及其基因与用途 |
| CA2931005A1 (en) | 2014-01-15 | 2015-07-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cartilage targeting agents and their use |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| KR20170095278A (ko) | 2014-12-05 | 2017-08-22 | 알렉시온 파마슈티칼스, 인코포레이티드 | 재조합 알칼리성 포스파타제를 이용한 발작 치료 |
| CN107405409B (zh) * | 2015-01-09 | 2022-03-22 | 阿森迪斯药物生长障碍股份有限公司 | Cnp前药 |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| PT3328416T (pt) * | 2015-07-30 | 2024-04-10 | Biomarin Pharm Inc | Utilização de variantes do péptido natriurético de tipo c para tratar as displasias esqueléticas |
| EP3689897A1 (en) * | 2015-07-31 | 2020-08-05 | Igisu Co., Ltd. | A cnp cyclic peptide and a medicament, external preparation and cosmetic containing the cyclic peptide |
| RU2745528C2 (ru) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
| EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| HUE057083T2 (hu) * | 2015-12-08 | 2022-04-28 | Biomarin Pharm Inc | C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére |
| WO2017118700A1 (en) * | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| NZ743488A (en) * | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| BR112018011008A2 (pt) * | 2016-01-08 | 2018-12-04 | Ascendis Pharma Growth Disorders As | agonistas de cnp de liberação controlada com ligação a npr-c baixa |
| CA3007976C (en) * | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| DK3400019T3 (da) * | 2016-01-08 | 2022-10-24 | Ascendis Pharma Growth Disorders As | CNP-prodrugs med bærerbinding ved ringenheden |
| US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US11186832B2 (en) | 2016-04-01 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
| WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| EP3484523A1 (en) * | 2016-07-13 | 2019-05-22 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| WO2018035420A1 (en) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| WO2018060314A1 (en) * | 2016-09-29 | 2018-04-05 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
| US20180194824A1 (en) | 2016-12-14 | 2018-07-12 | University Of Iowa Research Foundation | Musclin peptides and methods of use thereof |
| EP3574913A4 (en) * | 2017-01-24 | 2020-07-22 | Daiichi Sankyo Company, Limited | SMALL SIZE THERAPEUTIC AGENT |
| JP7152408B2 (ja) | 2017-03-10 | 2022-10-12 | キアペグ ファーマシューティカルズ アクチエボラグ | 遊離可能コンジュゲート |
| AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| TWI834720B (zh) | 2018-09-12 | 2024-03-11 | 瑞典商奎亞培格製藥公司 | 可釋放glp-1共軛物 |
| CN113423384B (zh) | 2019-02-11 | 2024-01-05 | 阿森迪斯药物生长障碍股份有限公司 | Cnp缀合物的干燥药物制剂 |
| JOP20210326A1 (ar) | 2019-06-12 | 2023-01-30 | Novartis Ag | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها |
| EP4013453A1 (en) * | 2019-08-12 | 2022-06-22 | BioMarin Pharmaceutical Inc. | Hydrophobic peptide salts for extended release compositions |
| MX2022003184A (es) * | 2019-09-16 | 2022-06-23 | Biomarin Pharm Inc | Variantes del cnp y sus conjugados. |
| IL298980A (en) * | 2020-06-12 | 2023-02-01 | Pharmain Corp | C-type natriuretic peptides and methods thereof in treating acute lung injury |
| EP4251150A1 (en) * | 2020-11-25 | 2023-10-04 | Prolynx LLC | Extended release hydrogel conjugates of c-natriuretic peptides |
| CN117042791A (zh) | 2021-02-12 | 2023-11-10 | 阿雷克森制药公司 | 碱性磷酸酶多肽及其使用方法 |
| RU2763661C2 (ru) * | 2021-03-31 | 2021-12-30 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ терапии и профилактики прогрессирования хронической почечной недостаточности |
| JP2024525562A (ja) | 2021-07-09 | 2024-07-12 | バイオマリン ファーマシューティカル インコーポレイテッド | 小児における骨格異形成症を治療するためのｃ型ナトリウム利尿ペプチドバリアント |
| IL313441A (en) * | 2021-12-07 | 2024-08-01 | Biomarin Pharm Inc | Cnp therapy |
| WO2023110758A1 (en) * | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| EP4452300A1 (en) * | 2021-12-20 | 2024-10-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment |
| AU2023232162A1 (en) * | 2022-03-11 | 2024-10-24 | Avirmax Biopharma Inc. | Compositions and methods for expressing therapeutics |
| AU2023276829A1 (en) | 2022-05-23 | 2024-10-31 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
| TW202419463A (zh) | 2022-11-02 | 2024-05-16 | 丹麥商諾佛 儂迪克股份有限公司 | Cnp化合物 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024128729A1 (ko) * | 2022-12-12 | 2024-06-20 | 주식회사 엘지생활건강 | 피부 개선용 화장료 조성물 |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| WO2024254405A2 (en) | 2023-06-07 | 2024-12-12 | Biomarin Pharmaceutical Inc. | High throughput screen for genetic variants associated with short stature |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991016342A1 (en) | 1990-04-20 | 1991-10-31 | Hisayuki Matsuo | Novel physiologically active peptide originating in hog |
| JP3026351B2 (ja) | 1990-07-13 | 2000-03-27 | 壽之 松尾 | ブタｃｎｐ遺伝子及び前駆体蛋白 |
| JP2930380B2 (ja) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | ブタ由来新規生理活性ペプチド（ｃｎｐ―５３） |
| JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトｃｎｐ遺伝子及び前駆体蛋白 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) * | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| WO1994020534A1 (en) | 1993-03-03 | 1994-09-15 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
| US5846932A (en) | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6136040A (en) | 1998-03-05 | 2000-10-24 | Washington University | Animal model with disrupted FGF-9 gene |
| IL125958A0 (en) * | 1998-08-27 | 1999-04-11 | Yeda Res & Dev | Animal model for fibroblast growth factor receptor associated chondrodysplasia |
| WO2000061631A1 (en) | 1999-04-12 | 2000-10-19 | Astrazeneca Ab | Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor |
| US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| ES2320101T3 (es) | 2000-10-16 | 2009-05-19 | Chugai Seiyaku Kabushiki Kaisha | Eritropoyetina conjugada con mono-peg. |
| JP2002178279A (ja) | 2000-12-12 | 2002-06-25 | Ulvac Japan Ltd | 基板搬送方法 |
| IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| AU2003214214A1 (en) * | 2002-03-18 | 2003-10-08 | Scios Inc. | Method for treating congestive heart failure |
| US6861236B2 (en) * | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
| AU2003285200A1 (en) | 2002-11-09 | 2004-06-03 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
| US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| SG159387A1 (en) | 2002-11-26 | 2010-03-30 | Biocon Ltd In | Modified natriuretic compounds, conjugates, and uses thereof |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7919255B2 (en) * | 2003-06-17 | 2011-04-05 | Otago Innovation Limited | Assessment of skeletal growth using measurements of NT-CNP peptides |
| EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
| AU2005232371B2 (en) | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| JP4972403B2 (ja) * | 2004-03-31 | 2012-07-11 | 一和 中尾 | 身長増加用組成物 |
| JP4825667B2 (ja) * | 2004-03-31 | 2011-11-30 | 一和 中尾 | 関節炎症治療剤又は予防剤 |
| JP2005292718A (ja) | 2004-04-05 | 2005-10-20 | Furukawa Electric Co Ltd:The | 光導波路、光導波路モジュールおよび光導波路の作成方法 |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| WO2006005140A2 (en) * | 2004-07-15 | 2006-01-19 | The University Of Queensland | Proteinaceous compounds and uses therefor |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| JP2010530222A (ja) | 2007-06-06 | 2010-09-09 | べーリンガー インゲルハイム インターナショナル ゲーエムベーハー | ナトリウム利尿融合タンパク質 |
| EP2171053B1 (en) * | 2007-07-20 | 2014-04-23 | Mayo Foundation for Medical Education and Research | Natriuretic polypeptides |
| EP2187921A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of gonadorelin as a therapeutic agent |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| WO2009086166A1 (en) | 2007-12-19 | 2009-07-09 | Ekr Therapeutics, Inc. | Room temperature stable, lyophilized natriuretic peptide formulations |
| ES2733355T3 (es) | 2008-02-01 | 2019-11-28 | Ascendis Pharma As | Profármaco que comprende un enlazador autoescindible |
| DK2277890T3 (en) * | 2008-05-23 | 2016-02-08 | Daiichi Sankyo Co Ltd | Peptide which is able to extend the half-life of a peptide of interest in the plasma |
| WO2010033217A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
| ES2904360T3 (es) | 2009-05-20 | 2022-04-04 | Biomarin Pharm Inc | Variantes de péptido natriurético de tipo C |
| WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
-
2010
- 2010-05-20 ES ES16192229T patent/ES2904360T3/es active Active
- 2010-05-20 PE PE2011001729A patent/PE20120792A1/es active IP Right Grant
- 2010-05-20 KR KR1020237032637A patent/KR20230142644A/ko not_active Application Discontinuation
- 2010-05-20 PL PL16192229T patent/PL3175863T3/pl unknown
- 2010-05-20 PT PT107783896T patent/PT2432489T/pt unknown
- 2010-05-20 DK DK16192229.9T patent/DK3175863T3/da active
- 2010-05-20 KR KR1020187004835A patent/KR102033680B1/ko active IP Right Grant
- 2010-05-20 PL PL10778389T patent/PL2432489T3/pl unknown
- 2010-05-20 EP EP21211450.8A patent/EP4029512A1/en active Pending
- 2010-05-20 CA CA2758581A patent/CA2758581C/en active Active
- 2010-05-20 DK DK10778389.6T patent/DK2432489T3/en active
- 2010-05-20 HU HUE16192229A patent/HUE057174T2/hu unknown
- 2010-05-20 CN CN201080023189.6A patent/CN102481330B/zh active Active
- 2010-05-20 BR BRPI1012783-6A patent/BRPI1012783B1/pt active IP Right Grant
- 2010-05-20 AR ARP100101761A patent/AR078044A1/es active IP Right Grant
- 2010-05-20 HU HUE10778389A patent/HUE032582T2/en unknown
- 2010-05-20 RU RU2011152007/10A patent/RU2573911C2/ru active
- 2010-05-20 TW TW99116187A patent/TWI471137B/zh active
- 2010-05-20 KR KR1020217006359A patent/KR20210027537A/ko not_active IP Right Cessation
- 2010-05-20 US US12/784,117 patent/US8198242B2/en active Active
- 2010-05-20 EP EP16192229.9A patent/EP3175863B1/en active Active
- 2010-05-20 BR BR122019026832-0A patent/BR122019026832B1/pt active IP Right Grant
- 2010-05-20 WO PCT/US2010/035586 patent/WO2010135541A2/en active Application Filing
- 2010-05-20 JP JP2012512035A patent/JP5718909B2/ja active Active
- 2010-05-20 ES ES10778389.6T patent/ES2608457T3/es active Active
- 2010-05-20 HR HRP20220057TT patent/HRP20220057T1/hr unknown
- 2010-05-20 PT PT161922299T patent/PT3175863T/pt unknown
- 2010-05-20 MX MX2011012277A patent/MX2011012277A/es active IP Right Grant
- 2010-05-20 AU AU2010249802A patent/AU2010249802B2/en active Active
- 2010-05-20 KR KR1020197029927A patent/KR102225470B1/ko active IP Right Grant
- 2010-05-20 KR KR1020117030424A patent/KR101831923B1/ko active IP Right Grant
- 2010-05-20 EP EP10778389.6A patent/EP2432489B1/en active Active
-
2011
- 2011-09-21 IL IL215287A patent/IL215287A/en active IP Right Grant
- 2011-09-28 ZA ZA2011/07087A patent/ZA201107087B/en unknown
- 2011-09-30 CL CL2011002430A patent/CL2011002430A1/es unknown
-
2012
- 2012-05-08 US US13/466,672 patent/US8598121B2/en not_active Ceased
- 2012-09-14 HK HK12109054.0A patent/HK1168279A1/zh unknown
-
2015
- 2015-01-23 US US14/604,262 patent/USRE46707E1/en active Active
- 2015-03-17 US US14/660,488 patent/US20160256553A1/en not_active Abandoned
-
2016
- 2016-10-24 US US15/332,793 patent/US20170051033A1/en not_active Abandoned
- 2016-12-19 HR HRP20161739TT patent/HRP20161739T1/hr unknown
-
2017
- 2017-07-11 US US15/646,822 patent/USRE48267E1/en active Active
-
2022
- 2022-01-19 FI FIC20220003C patent/FIC20220003I1/fi unknown
- 2022-01-20 HU HUS2200004C patent/HUS2200004I1/hu unknown
- 2022-01-28 FR FR22C1004C patent/FR22C1004I2/fr active Active
- 2022-02-01 NO NO2022003C patent/NO2022003I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161739T1 (hr) | VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa | |
| JP2012527244A5 (hr) | ||
| EP2330124B1 (en) | Hybrid polypeptides with selectable properties | |
| Elliott et al. | Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization | |
| CN105722526B (zh) | 选择性pyy化合物及其用途 | |
| JP2008530130A (ja) | Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド | |
| US20130281374A1 (en) | Dpp-iv resistant gip hybrid polypeptides with selectable properties | |
| US9969788B2 (en) | Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences | |
| JP2009213477A5 (hr) | ||
| US10118955B2 (en) | C-terminal fragments of glucagon-like peptide-1 (GLP-1) | |
| EP2057188A2 (en) | Dpp-iv resistant gip hybrid polypeptides with selectable properties | |
| HRP20210635T1 (hr) | Novi mutant humanog seruma albumina | |
| Ueda et al. | Identification of alpha atrial natriuretic peptide [4–28] and [5–28] in porcine brain | |
| Thim et al. | The amino acid sequence of pancreatic spasmolytic polypeptide | |
| CN101671396B (zh) | 与胶原蛋白特异结合的血管内皮生长因子及其应用 | |
| Yoshihara et al. | Isolation and sequence determination of frog C-type natriuretic peptide | |
| TWI300414B (en) | Modified peptide yy and conjugates thereof | |
| JP4613063B2 (ja) | ペプチドアミド化方法 | |
| Boumaiza et al. | Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1 | |
| CN114644717A (zh) | 一种重组人胰高糖素样肽-1及其构建方法和应用 | |
| JP4276462B2 (ja) | 修飾ペプチドの製造方法 | |
| US20150259394A1 (en) | Chemically and thermodynamically stable insulin analogues and improved methods for their production | |
| WO2006108686A2 (en) | Bnp agonists | |
| JPH11515022A (ja) | 成長促進物質 | |
| Deng et al. | Insulin chains as efficient fusion tags for prokaryotic expression of short peptides |